Search Within

Maurizio Scaltriti

Formats
  1. Journal Article (94)
  2. Meeting Abstract (68)
  3. Book Section (3)
  4. Review (3)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. GSK Faculty (89)
  2. Sloan Kettering Institute Postdocs (86)
  3. Department of Medicine (80)
  4. Solid Tumor Oncology Division (79)
  5. Human Oncology and Pathogenesis Program (60)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (55)

More Groups

People
  1. Jose Baselga (63)
  2. Pedram Razavi (32)
  3. David Hyman (27)
  4. Michael Berger (27)
  5. Sarat Chandarlapaty (26)
  6. Emiliano Cocco (25)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2022 (6)
  4. 2021 (16)
  5. 2020 (27)
  6. 2019 (26)

More Years

Publications
  1. Cancer Research (37)
  2. Annals of Oncology (16)
  3. Clinical Cancer Research (12)
  4. Cancer Discovery (8)
  5. Journal of Clinical Oncology (8)
  6. Cancer Cell (6)

More Publications

Publishers
  1. American Association for Cancer Research (59)
  2. Nature Publishing Group (20)
  3. Oxford University Press (17)
  4. Elsevier Inc. (12)
  5. American Association for the Advancement of Science (10)
  6. American Society of Clinical Oncology (9)

More Publishers

Results (170)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
    Journal Article

    Yang, C.; Li, Z.; Bhatt, T.; Dickler, M.; Giri, D.; Scaltriti, M.; Baselga, J.; Rosen, N.; Chandarlapaty, S.
    Oncogene (2017)

    Fulltext@MSK | Save
  • PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
    Journal Article

    Toska, E.; Osmanbeyoglu, H. U.; Castel, P.; Chan, C.; Hendrickson, R. C.; Elkabets, M.; Dickler, M. N.; Scaltriti, M.; Leslie, C. S.; Armstrong, S. A.; more...
    Science (2017)

    Fulltext@MSK | Save
  • Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
    Journal Article

    Lopez-Albaitero, A.; Xu, H.; Guo, H.; Wang, L.; Wu, Z.; Tran, H.; Chandarlapaty, S.; Scaltriti, M.; Janjigian, Y.; de Stanchina, E.; more...
    OncoImmunology (2017)

    Fulltext@MSK | Save
  • Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
    Journal Article

    Mizrachi, A.; Shamay, Y.; Shah, J.; Brook, S.; Soong, J.; Rajasekhar, V. K.; Humm, J. L.; Healey, J. H.; Powell, S. N.; Baselga, J.; more...
    Nature Communications (2017)

    Fulltext@MSK | Save
  • The emerging role of serum/glucocorticoid-regulated kinases in cancer
    Journal Article

    Castel, P.; Scaltriti, M.
    Cell Cycle (2017)

    Fulltext@MSK | Save
  • Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status
    Meeting Abstract

    Razavi, P.; Cecchi, F.; Ross, D. S.; Middha, S.; Zehir, A.; Arcila, M. E.; Hembrough, T. A.; Berger, M. F.; Scaltriti, M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Tuvy, Y.; Bouvier, N.; Riches, J. C.; Margolis, M.; Millang, B. M.; Scott, S. N.; Kundra, R.; Castel, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)
    Meeting Abstract

    Alsina, M.; Hierro, C.; Sastre, J.; Guardeno, R.; Lopez, C.; Pineda, E.; Aranda, E.; Manzano, J. L.; Galan, M.; Longo, F.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Tumor-specific PI3K inhibition by targeted delivery in head and neck squamous cell carcinoma
    Meeting Abstract

    Mizrachi, A.; Shamay, Y.; Shah, J. K.; Brook, S.; Rajasekhar, V. K.; Humm, J. L.; Baselga, J.; Heller, D. A.; Haimovitz-Friedman, A.; Scaltriti, M.
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy
    Meeting Abstract

    Scaltriti, M.; Carmona, F. J.; Toska, E.; Cocco, E.; Hyman, D.; Cutler, R.; Avogadri-Connors, F.; Wick, M. J.; Papadopoulos, K. P.; Lalani, A. S.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save